To think that Big Pharma would overlook the significance of P2 results, and somehow not be interested in a breakthrough drug because of low cash balance is mind boggling.
We're not talking about some pre-clinical IP, or red ocean market like MS....we are talking about a potential $6B blockbuster drug that "may" also unleash the power of their Gene-Therapy and road to FDA approval.
Diamond has been consistent about the cash position since early this year...and the mention of partnership of sorts.
With Goolsbee and Dr Price involved, I think they have the maturity to make good decisions this time around, they're aiming big.
All will be revealed, eyes on the ball.
ANP Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
